INOVIO PHARMACEUTICALS, INC. Derivative Liability, Current
INOVIO PHARMACEUTICALS, INC. (INO) had Derivative Liability, Current of $25.02 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DerivativeLiabilitiesCurrent · last filed 2026-08-12
- 2026-06-30: Derivative Liability, Current $25.02M.
- 2026-03-31: Derivative Liability, Current $24.93M.
- 2025-12-31: Derivative Liability, Current $29.07M.
- 2025-09-30: Derivative Liability, Current $50.38M.
| Period end | Derivative Liability, Current |
|---|---|
| 2026-06-30 | $25.02M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $24.93M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $29.07M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $50.38M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $11.42M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $9.54M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $13.26M 10-K · filed 2026-03-12 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |